AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...
That said, RemeGen and Seagen are targeting gastric, bladder and low HER2 breast cancer first with disitamab vedotin, minimising direct clashes with Enhertu and Kadcyla in the near term at least.
Researchers have seen an 'alarming' rise in breast cancer rates in women under 40, with some states experiencing a 32% ...
Imaging technology developed and refined at the University of Waterloo promises better detection and treatment of breast ...
Breast cancer incidence trends in U.S. women under 40 vary by geography and supports incorporating location information with established risk factors into risk prediction, improving the ability to ...
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit offers insight into the new NCCN guidelines, discusses the new ...
A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study published in the journal Nature.
Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...
A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...
Using the nanostructures found on butterfly wings, scientists have developed a simple and inexpensive way to analyze cancerous tissues.
More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.